• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.13% Nasdaq Up0.70%

    Agios Pharmaceuticals, Inc. (AGIO)

    114.43 Up 4.76(4.34%) Dec 26, 4:00PM EST
    |After Hours : 114.25 Down 0.18 (0.16%) Dec 26, 7:59PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Agios Pharmaceuticals, Inc.
    38 Sidney Street
    2nd Floor
    Cambridge, MA 02139
    United States - Map
    Phone: 617-649-8600
    Website: http://www.agios.com

    Index Membership:N/A
    Full Time Employees:96

    Business Summary 

    Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its product candidates include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. The company is also developing AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Agios Pharmaceuticals, Inc.

    Corporate Governance 
    Agios Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 7. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 9; Compensation: 2.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. David P. Schenkein M.D., 57
    Chief Exec. Officer and Director
    Dr. Lewis Clayton Cantley Ph.D., 65
    Co-Founder, Director, Member of Scientific Advisory Board and Member of Science & Technology Committee
    Mr. Glenn Goddard , 43
    Principal Financial Officer, Principal Accounting Officer and Sr. VP of Fin.
    Mr. John Duncan Higgons M.Sc (Economics), 59
    Chief Operating Officer
    Dr. Scott Biller Ph.D., 58
    Chief Scientific Officer
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders